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The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers 
(NSCLC) and is a major target for new therapies. Specific EGFR tyrosine kinase inhibitors (TKIs) have been de-
veloped and used for the treatment of advanced NSCLC. The clinical response, however, varies dramatically 
among different patient cohorts. Females, East Asians, non-smokers, and patients with adenocarcinoma usually 
show higher response rates. Meanwhile, a number of biological factors are also associated with EGFR-TKIs re-
sponsiveness. In order to better understand the predictive value of these biomarkers and their significance in 
clinical application we prepared this brief review. Here we mainly focused on EGFR somatic mutations, MET 
amplification, K-ras mutations, EGFRvIII mutation, EGFR gene dosage and expression, HER2 gene dosage and 
expression, and Akt phosphorylation. We think EGFR somatic mutation probably is the most effective molecular 
predictor for EGFR-TKIs responsiveness and efficacy. Mutation screening test can provide the most direct and 
valuable guidance for clinicians to make decision on EGFR-TKIs therapy. 
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Introduction 
Lung cancer is one of the most common human 
cancers and the leading cause of cancer death world-
wide (1). Lung cancer is generally classified into two 
histological types, small cell lung cancer (SCLC) and 
non–small cell lung cancer (NSCLC). NSCLC accounts 
for approximately 85% of the cases and it is further 
divided into squamous-cell carcinoma (SSC), adeno-
carcinoma (AC), large cell carcinoma, and others (2). 
Adenocarcinoma has become the most prevalent sub-
type of NSCLC in recent decades (3, 4). The treatment 
of lung cancer is mainly based on the stage of cancer, 
patients’ performance status, comorbidity, etc (5). For 
patients with early stage disease (stage I or II) surgical 
resection is considered the primary therapeutic choice. 
It is worth taking notice, however, that majority of 
NSCLC cases have reached locally advanced (stage III) 
or metastatic stage (stage IV) at the time of diagnosis 
(6), and chemotherapy is usually recommended as the 
first line therapy.   
Chemotherapy is often considered too toxic, par-
ticularly for elderly patients and patients with poor 
performance status. The well-established plati-
num-based regimen can only bring modest survival 
benefit by increasing the median survival time about 
three months in average (7, 8). In recent years more 
effort has been put onto the development of molecu-
lar-targeted drugs.   
Epidermal growth factor receptor (EGFR) is 
overexpressed in the majority of NSCLC and it is an 
important target in the treatment of NSCLC. EGFR is a 
member of the family of EGF-related tyrosine kinase 
receptors. Upon ligands binding, the receptors homo- 
or hetero-dimerize. Subsequently, it activates recep-
tors’ intrinsic tyrosine kinase activity and broad 
downstream signaling cascades, mainly including 
Ras-Raf-MAP-kinase pathway, PI3K-Akt pathway, 
and STAT pathway. All these have strong stimulatory 
effect on cell proliferation, differentiation, survival, 
angiogenesis and migration (9-11). EGFR has emerged 
as a critical tumorigenic factor in the development and 
progression of NSCLC (12-14). Two specific EGFR ty-
rosine kinase inhibitors (TKIs), gefitinib (ZD1839, Ir-
essa) and erlotinib (OSI-774, Tarceva), have been de-
veloped and used clinically in the treatment of ad-
vanced NSCLC. These two drugs disrupt EGFR sig-
naling by competing with adenosine triphosphate 
(ATP) for the binding sites at tyrosine kinase domain, Int. J. Med. Sci. 2008, 5 
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and thus inhibiting the phosphorylation and activa-
tion of EGFRs and the downstream signaling network. 
Both agents can induce dramatic clinical response in 
patients who fail chemotherapy. Erlotinib and gefit-
i n i b  h a v e  b e e n  s h o w n  t o  h a v e  s u r v i v a l  b e n e f i t  i n  
Caucasians and Asians respectively when compared 
to placebo in controlled double-blinded randomized 
phase III trials (15, 16). However, among unselected 
NSCLC patients the objective response rate is only 
about 10% (17, 18). Female patients, nonsmokers, East 
Asians, and patients with lung adenocarcinoma are 
noted to have higher response rates (17-19). In addi-
tion, many laboratories have found a number of other 
factors which are associated with EGFR-TKIs sensitiv-
ity. In order to better understand and interpret these 
basic and clinical research knowledge and accelerate 
the translation of research findings into daily medical 
practice, we reviewed the literature and carefully 
evaluated the predictive value of these biomarkers. 
We hope this brief review could provide useful infor-
mation for clinicians, patients, and research profes-
sionals, help clinicians to select the right subgroup of 
NSCLC patients for EGFR-TKI therapy with high fre-
quency of success, and to stimulate future research 
interest and effort in targeted therapy for NSCLC pa-
tients.  
1. Somatic mutations in EGFR 
Somatic mutation is the mutation that occurs 
only in somatic cells, which are in contrast to germ 
cells. A number of somatic mutations have been iden-
tified in the EGFR gene in NSCLC. In general these 
mutations can be classified into three major types: 
in-frame deletion, insertion, and mis-sense mutation. 
Most of the mutations are located in the tyrosine 
kinase coding domain (exons 18-21) of the EGFR gene. 
The amino acids 746~753 encoded by exon 19 and 
amino acid 858 encoded by exon 21 are two mutation 
hotspots, which accounts for over 80% of all the de-
tected mutations.   
Gefitinib sensitive mutations 
A number of retrospective studies have reported 
that two activating mutations, small in-frame deletion 
in exon 19 (746~753) and substitution of leucine for 
arginine at amino acid 858 in exon 21 (L858R), have 
striking correlation with EGFR-TKI sensitivity (20-28). 
This discovery has been claimed as the most signifi-
cant molecular event in lung cancer (29). Both activat-
ing mutations are able to enhance kinase activity of 
EGFR and the activation of its downstream signaling, 
and play a pivotal role in supporting NSCLC cell sur-
vival (20, 30). When specific EGFR-TKIs are applied, 
the excessive survival signals that cancer cells are 
“addicted to” are counteracted and dramatic apop-
tosis occurs (30, 31).   
Seven phase II prospective studies (32-38) per-
formed with gefitinib or erlotinib in EGFR mutation 
positive NSCLC patients have also demonstrated over 
87% of response and disease control rate, and the du-
ration of progression free survival ranges from 7.7 to 
14 months, which is much longer than those reported 
in the literature by chemotherapy or other targeted 
therapy in unselected patient population (usually 4~6 
months). In addition, the response rates were quite 
similar regardless race, gender, histology, or smoking 
history (Table 1). Some of the studies have suggested 
better quality of life and longer survival occurred in 
patients treated with gefitinib or erlotinib (26, 27, 39). 
All these demonstrate that EGFR activating mutations 
are effective predictor for EGFR-TKIs responsiveness 
and prognosis. Prospective randomized studies, 
however, are still needed to compare EGFR-TKIs with 
chemotherapy in NSLCLC patients with positive 
EGFR mutation to establish the role of EGFR-TKIs as 
the treatment choice in such patients. 
 
Table 1 Prospective studies of gefitinib/erlotinib in EGFR mutation positive NSCLC patients 
Author  No. of par-
ticipating 
patients with 
EGFR muta-
tions  
Ethnicity EGFR  mutation  screening 
method 
Overall 
response 
and disease 
control rate 
Complete 
response 
(%) 
 
Partial 
response 
(%) 
 
Stable 
disease 
(%) 
Median 
progres-
sion-free 
survival 
(Months) 
Yoshida K et al 
(35) 
21  Japanese  Gene scan & cycleave real-time 
quantitative PCR technology 
91%  3 (14%)  16 (76%)  0  7.7  
Sunaga N, et al (32)  21   Japanese  Sequencing  91%  3 (14%)  13 (62%)  3 (14%)  12.9  
Inoue A, et al (34)   16   Japanese  Sequencing  88%  0  12 (75%)  2 (13%)  9.7  
Asahina H, et al (33)  16   Japanese  Sequencing  81%  2 (13%)  10 (62%)  1 (6%)  8.9  
Paz-Ares L, et al (36)  21  Caucasian Gene scan & TaqMan assay  91%  6 (29%)  13 (62%)  0  >8  
van Zandwijk N, et 
al (37) 
13   Caucasian Sequencing and gene scan  92%  1 (8%)  10 (77%)  1(8%)  14  
Sequist LV, et al (38)  31   Asian & 
others 
Sequencing  94%  1 (3%)  16 (52%)  12 (39%) 9.2 
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Deletion in exon 19 and L858R are usually more 
common in women, East Asians, light smokers (less 
than 15 pack-years), and patients with adenocarci-
noma (reviewed in (40)). Some studies have reported 
that exon 19 deletion is superior to L858R in predic-
tion of response rates and survival (26, 39, 41). How-
ever, conflict results indicate there is no significant 
difference observed between these two mutations (33, 
34). More studies are required to clarify this issue. 
EGFR-TKIs resistant mutaions 
T790M, D761Y, L747S, and insertion in exon 20 
are associated with resistance to EGFR-TKIs (42-47). 
T790 is located at the key position in ATP binding cleft 
of EGFR and is considered the gatekeeper residue. The 
introduction of T790M mutation increases ATP affin-
ity of receptors, which relatively attenuates the bind-
ing of EGFR-TKIs (48). T790M is mainly present in 
relapsed tumors after an initial response and secon-
dary to EGFR-TKIs therapy (42, 43), and it accounts 
for about half of acquired resistance to gefitinib or el-
otinib (44). Therefore, T790M has been considered a 
specific marker for acquired resistance to EGFR-TKIs. 
L747S, D761Y and insertions in exon 20 also confer 
m o d e s t  r e s i s t a n c e  t o  E G F R - T K I s .  H o w e v e r ,  t h e y  a r e  
not as common as T790M among NSCLC patients 
with acquired resistance to EGFR-TKIs.   
2. MET amplification 
MET is a high affinity tyrosine kinase receptor 
for hepatocyte growth factor (HGF)/ scatter factor. 
The binding of HGF results in autophosphorylation of 
MET at multiple tyrosine residues and activation of 
many downstream signaling components, which 
produce profound effect on cellular motility, growth, 
survival, invasion, and metastasis (49). Alteration of 
MET pathway contributes to the development and 
progression of a number of human tumors. Amplifica-
tion of the MET gene has been detected in gastric can-
cers (10~20%) and esophageal cancers (50, 51). In ad-
dition, activating mutations of MET are observed in 
papillary renal carcinoma (52). MET amplification has 
been observed in NSCLC and it is associated with 
EGFR-TKI resistance (53, 54). Its incidence is about 
21% (9 out of 43) among patients with acquired resis-
tance. Among untreated patients it occurs much less 
frequently (about 3%) (53). MET amplification is able 
to activate ERBB3 (HER3)-dependent PI3K/Akt 
pathway, and ultimately lead to gefitinib resistance 
(54). Its occurrence is independent of T790M (53). 
3. K-ras mutation 
Ras is one of the important molecules in the 
downstream of EGFR signaling pathway. Ras is able 
to activate serine/theronine kinase Raf, the mito-
gen-activated protein kinases ERK1 and ERK2, and a 
number of nuclear proteins to promote cell prolifera-
tion. Ras genes, especially K-ras, have been implicated 
in the pathogenesis and prognosis of lung cancer (55). 
Mutated  K-ras  can been observed among 20~30% 
NSCLC patients. Majority of the mutations (approxi-
mately 80~90%) are guanine to thymine transversion 
in codon 12, which results in constitutive activation of 
K-ras protein (56, 57). NSCLC patients with K-ras mu-
tations are associated with unfavorable prognosis 
(58-60).  
The correlation of K-ras mutations with EGFR 
mutations and gefitinib response has been investi-
gated by several groups (61-63). In general, the muta-
tions of EGFR and K-ras are mutually exclusive. 
NSCLC patients with K-ras mutations have poor sen-
sitivity to EGFR-TKIs (25, 64). Screening K-ras muta-
tion among NSCLC patients who are negative for 
EGFR mutations could provide additional information 
to avoid EGFR-TKIs.   
4. Type III epidermal growth factor receptor mu-
tation  
Type III deletion mutation (EGFRvIII) is the dele-
tion of exons 2~7, a 801bp fragment of EGFR cDNA, 
which produces a truncated receptor lacking a portion 
of extracellular ligand binding domain (65). The trun-
cated receptor, however, is oncogenic. It has constitu-
tive kinase activity, which is strong enough to activate 
downstream signaling cascades and gives cells growth 
advantage (66, 67). EGFRvIII has been identified in a 
number of human solid tumors, including glioblas-
toma, breast cancer, ovarian cancer, prostate cancer, 
and lung caner (66-69). The incidence of EGFRvIII in 
NSCLC varies among studies. Okamoto et al and 
Garcdia et al have identified 16% (5 of 32) and 39% (30 
of 76) of EGFRvIII using immunochemistry staining 
(66, 70). In contrast, low detected rates have been re-
p o r t e d  u s i n g  R T - P C R  ( 2 . 8 % ~ 3 . 2 %  o r  u n d e t e c t a b l e )  
(71-73). The study performed in transgenic mouse has 
revealed that EGFRvIII mutant cancer cells are rela-
tively resistant to EGFR-TKIs, but sensitive to irre-
versible EGFR inhibitor (71) and anti-EGFR antibody 
806 (74).   
5. EGFR gene dosage 
Gene dosage is the number of copies of a gene 
present in a cell or nucleus. An increase in gene dos-
age means the gene is amplified. Gene amplification is 
a molecular mechanism responsible for oncogene 
overexpression. By production of multiple copies of a 
particular gene or genes, the phenotype that the gene 
confers is amplified in the cell. High copies of EGFR 
(amplification or high polysomy) have been detected 
in approximately 30% of NSCLC patients using fluo-Int. J. Med. Sci. 2008, 5 
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rescence in situ hybridization (FISH), and it is usually 
associated with poor clinical prognosis (75). High 
copies of EGFR probably is an effective predictor for 
better treatment response to EGFR-TKIs (Table 2)(22, 
23, 76, 77). Patients who have increased copies of 
EGFR gene show significant survival benefit from 
EGFR-TKIs treatment in both Phase II (23, 78) and 
Phase III clinical trials (Iressa Survival Evaluation in 
Lung cancer and BR.21) (79, 80) (Table 2).   
High EGFR copy number is frequently correlated 
with EGFR somatic mutations(22, 27, 31, 81). This casts 
doubt about the independent predictive value. Addi-
tional preclinical and clinical studies with large sam-
ple size are paramount to resolving this issue. Since 
the mutation rate of EGFR is much lower among Cau-
casians (~10%) comparing with Asians (30~50%) and a 
substantial portion of patients without EGFR muta-
tions still benefit from EGFR-TKIs treatment, in-
creased  EGFR g e n e  c o p y  n u m b e r  c o u l d  p l a y  i t s  
unique role in predicting EGFR-TKIs susceptibility. 
Japanese patients with EGFR gene amplification, 
however, do not benefit from gefitinib treatment (72). 
 
Table 2 Detected EGFR copy number using FISH and EGFR-TKI treatment response in NSCLC 
Study subjects  Scoring criteria  Result  Conclusion 
FISH negative  with no or low genomic gain (≤4copies in 40% 
cells) 
68% 
high level of polysomy (≥4copies in 40% cells) 
81 
(Southwest Oncology 
Group study 0126) 
  FISH Positive  
Gene amplification 
 (EGFR/chr7≥2, or≥15 copies per cell in ≥10% 
cells) 
 
32% 
EGFR copy number is associ-
ated with improved survival 
after gefitinib therapy (78) 
Disomy  ≤2 copies in >90% of cells  35% 
Low trisomy  ≤2 copies in ≥40% of cells, 3 copies in 10%–40% of 
the cells, ≥4 copies in <10% of cells 
17% 
High trisomy  ≤2 copies in ≥40% of cells, 3 copies in ≥40% of cells, 
≥4 copies in <10% of cells 
2% 
Low polysomy  ≥4 copies in 10%–40% of cells  14% 
High polysomy  ≥4 copies in ≥40% of cells  20.0% 
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Gene amplification  EGFR/chr7≥2, or≥15 copies per cell in ≥10% cells  13% 
Gene amplification and high 
polysomy has higher response 
rate and better survival (23) 
Disomy  ≤2 copies in >90% of cells  69% 
Low trisomy  ≤2 copies in ≥40% of cells, 3 copies in 10%–40% of 
the cells, ≥4 copies in <10% of cells 
16% 
High trisomy  ≤2 copies in ≥40% of cells, 3 copies in ≥40% of cells, 
≥4 copies in <10% of cells 
24% 
Low polysomy  ≥4 copies in 10%–40% of cells  27% 
High polysomy  ≥4 copies in ≥40% of cells  17% 
370 
Phase III Iressa Survival 
Evaluation in Lung Can-
cer  
 
Gene amplification  EGFR/chr7≥2, or≥15 copies per cell in ≥10% cells  14% 
 EGFR gene copy number is a 
predictor for survival benefit 
from gefitinib (80).  
Disomy  ≤2 copies in >90% of cells  10% 
Low trisomy  ≤2 copies in ≥40% of cells, 3 copies in 10%–40% of 
the cells, ≥4 copies in <10% of cells 
18% 
High trisomy  ≤2 copies in ≥40% of cells, 3 copies in ≥40% of cells, 
≥4 copies in <10% of cells 
2% 
Low polysomy  ≥4 copies in 10%–39% of cells  24% 
High polysomy  ≥4 copies in ≥40% of cells  34% 
125 
Phase III clinical trial 
BR.21 study 
Gene amplification  EGFR/chr7≥2, or≥15 copies per cell in ≥10% cells  11% 
High copies of EGFR was 
associated with survival bene-
fit from Erlotinib (79). 
FISH negative  no or low genomic gain (≤4copies in 40% cells)  68%  183 
Pooled study subjects 
from Italy and SWOG 
study 0126 
FISH Positive   Gene amplification  
(EGFR/chr7 ≥2, or ≥15 copies per cell in ≥10% 
cells) 
 
32% 
EGFR gene copy number is an 
independent predictive bio-
marker for survival (77) 
Table 3 EGFR protein expression and EGFR-TKI treatment response 
Sample size  Scoring criteria  Results  Conclusion 
Negative  <10% cells positive for membranous stain-
ing 
43%  325 (Phase III clinical trial 
BR.21 study) 
  Positive  ≥10% of tumor cells positive for membra-
nous staining 
57% 
EGFR expression is associated 
with erlotinib treatment re-
sponse(79) 
0~99  Negative 
100~199 
40% 
200~299 
100 
Positive 
300~400 
58% 
EGFR protein status is associ-
ated with gefitinib treatment 
response (23) 
0~99  Negative 
100~199 
39% 
200~299 
200 (Pooled study subjects 
from Italy and SWOG 
study 0126)  Positive 
300~400 
61% 
EGFR protein status is associ-
ated with treatment response 
(77) Int. J. Med. Sci. 2008, 5 
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0~99  Negative 
100~199 
30% 
200~299 
379 (Phase III Iressa Sur-
vival Evaluation in Lung 
Cancer)  
  Positive 
300~400 
70% 
EGFR protein status is associ-
ated with treatment response 
(80) 
0/1+  Negative to faint immunoreactive cells  54%  50  
2+/3+  Medium to strong immunoreactive cells  46% 
EGFR protein is not a signifi-
cant predictive factor for re-
sponse to gefitinib (88) 
*Percentage of positive tumor cells per slides ×dominant intensity pattern of staining 
6. EGFR protein expression  
Overexpression of EGFR protein is very common 
in NSCLC patients (40-80%) (13, 14), and it is associ-
ated with aggressive clinical behaviors and poor 
prognosis (82-87). The relationship between EGFR 
protein level and EGFR-TKIs sensitivity has been 
studied intensively. Both positive (23, 77, 79, 80) and 
negative correlation (88, 89) have been reported (Table 
3). The conflict observations partially could be attrib-
uted to the methodology (immunohistochemistry 
staining, IHC) applied for EGFR protein quantification 
because different laboratories use different antibodies, 
different scoring systems, and different protocols. 
EGFR protein is often associated with EGFR gene copy 
number (23, 75, 90, 91). Hirsch et al have recently 
suggested that patients with FISH and IHC double 
positive (approximately 23%) probably can benefit 
more from EGFR-TKIs (77).   
7. HER2 expression and gene dosage 
HER2 is another member of erbB transmembrane 
receptor family. It has intrinsic kinase activity. HER2 
is known to be a preferred coreceptor for EGFR in the 
process of EGFR heterodimerization. Increased ex-
pression of HER2 is associated with inferior survival 
in NSCLC patients, and high EGFR and HER2 coex-
pression has additive impact on unfavorable progno-
sis (92). Overexpression of HER2 protein is not associ-
ated with gefitinib response and survival (76, 93). 
Neither is HER2 cop y n umber (78). However, HER2 
amplification could predict gefitinib sensitivity and 
survival among NSCLC patients with increased EGFR 
copy number (76, 94).   
8. Akt phosphorylation  
The phosphatidylinositol 3’-kinases (PI3K)/Akt 
pathway is one of the important downstream signal 
transduction pathways of EGFR. It plays critical role 
in regulating cell survival and apoptosis. Akt activa-
tion is able to protects cells from apoptosis by inacti-
vating pro apoptotic proteins (95, 96).  Increased 
PI3K/Akt activity has been observed in NSCLC. Posi-
tive p-Akt expression is associated with better gefit-
inib responsiveness and prognosis (77, 97, 98). Con-
flicting result have also indicated that p-Akt is not as-
sociated with EGFR-TKI efficacy (99).  
Gene expression signature and mass spectrometry 
Gene expression signature and mass 
spectrometry are fast growing area in cancer research. 
Although both biotechnologies are costly, they are 
robust for new biomarkers discovery. For patients 
who are negative for EGFR mutations and/or other 
markers, gene expression and mass spectrometry 
analysis probably could introduce new insight into 
clinical practice to assure better clinical outcomes. By 
comparing the gene expression patterns of gefitinib 
sensitive and gefitinib resistant lung cancer, Balko and 
Coldren  et al have found several novel markers 
associated with gefitinib sensitivity (100, 101). In 
addition, they have generated a multivariate model, 
which is supposed to provide more accurate 
prediction for EGFR-TKI sensitivity than single 
biomarkers or clinical characteristics (100).   
Mass spectrometry is currently the most 
powerful analytic proteomic tool. Using mass 
spectrometry Taguchi et al have performed a 
multicohort cross-institutional study to investigate 
serum predictive biomarkers for clinical outcome after 
EGFR-TKIs treatment. They have identified eight 
distinct peaks and developed an algorithm, which 
could be used for patients selection and to predict 
prognosis after EGFR-TKI treatment (102). However, 
there are some concerns regarding the predictive 
value because the identities of the eight discriminatory 
peaks remain unknown and there are no other 
validation tests performed beyond their laboratory.   
Discussion 
Identifying a panel of predictive markers is im-
portant for selection of advanced NSCLC patients for 
EGFR-TKI therapy. Although several important 
demographic and clinical factors are associated with 
treatment response, EGFR somatic mutations are still 
the most effective predictor for EGFR-TKI sensitivity. 
EGFR mutation screening could be number one test to 
provide the most direct and valuable information to 
help clinicians to make treatment decision. Among 
NSCLC patients with EGFR-TKI susceptible mutations 
7 0 %  o f  o b j e c t i v e  r e s p o n s e  r a t e  o r  h i g h e r  c a n  b e  e x -
pected with progression-free survival of at least 7.7 
months upon gefitinib/erlotinib treatment. Moreover, 
mutation analysis can also provide insight into resis-
tance mechanisms to EGFR-TKIs by NSCLC cells.   Int. J. Med. Sci. 2008, 5 
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The question, however, is who should have 
EGFR mutation screening test. We recommend all ad-
vanced NSCLC patients to consider mutation test be-
fore EGFR-TKIs treatment. For female patients with 
favorable clinical factors such as adenocarcinoma 
and/or low exposure to smoking, mutation test might 
not be necessary if the patients object to the test or the 
test is not available. Male patients with squamous-cell 
carcinoma or heavy smoking history and failing stan-
dard chemotherapy had little possibility responding to 
EGFR-TKI. It is prudent to test EGFR mutation before 
starting EGFR-TKI treatment.   
Regarding the specimen and the method used for 
mutation analysis, we do not think the answer is uni-
versal, and the choices are multiple. By now direct 
sequencing is the most commonly used method for 
EGFR mutation screening although the sensitivity is 
often concerned, especially for heterogeneous speci-
mens, such as pleural effusion drainage, blood or 
plasma. In addition, a number of genotyping methods 
with high sensitivity have been developed for EGFR 
mutation screening, such as single-strand conforma-
tion polymorphism (SSCP), scorpion allele specific 
PCR, mutation enriched PCR, and peptide nucleic 
acid-locked nucleic acid (PNA-LNA) PCR clamp. Most 
of them are able to detect even one EGFR mutant tu-
mor cell with the presence of up to 1000-2000 normal 
cells(103-106). However, these sensitive methods have 
only been tested in small number of patients, and they 
are available in limited numbers of research laborato-
ries. These methods are also needed to be standard-
ized and validated. Therefore, under current situation 
direct sequencing probably is a mature method which 
could be used in health institutions for routine clinical 
mutation screening. For the commonly known muta-
tions, such as deletion in exon 19, L858R, and T790M, 
gene scan, Scorpion allele specific PCR, and TaqMan 
genotyping assay are applicable. These methods are 
highly sensitive and easy to handle.   
Among EGFR mutation negative patients, other 
predictive markers, such as EGFR copy number de-
tected by FISH or K-ras mutation could provide im-
portant information in deciding the use of EGFR-TKIs 
for NSCLC patients. 
Conclusions 
EGFR mutation is the most effective molecular 
predictor of sensitivity in patients with advanced 
NSCLC to EGFR-TKIs treatment. Almost 75% of 
patient with EGFR mutations will have objective 
response to either gefitinib or erlotinib. Other 
molecular markers or methods, such as EGFR gene 
copy numbers, K-ras mutation, gene expression 
signature or serum protein profiles by mass 
spectroscopy may add additional value but require 
further studies. 
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